Actively Recruiting

Phase 2
Age: 18Years +
All Genders
NCT04220749

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

Led by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Updated on 2020-09-04

68

Participants Needed

1

Research Sites

396 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

The goal of this randomized phase II study is a formal comparison of radiotherapy versus trans-oral surgery as the primary treatment of HPV-negative patients with early-stage oropharyngeal carcinoma.

CONDITIONS

Official Title

Radiotherapy vs. Trans-Oral Surgery for HPV-Negative Oropharyngeal Squamous Cell Carcinoma

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Age 18 years or older
  • Willing to provide informed consent
  • ECOG performance status between 0 and 2
  • Histologically confirmed squamous cell carcinoma
  • HPV-negative tumor confirmed by negative p16 status, PCR, or in-situ hybridization; equivocal HPV status allowed
  • Primary tumor located in the oropharynx (tonsil, soft palate, base of tongue, oropharynx walls)
  • Tumor stage T1 or T2 with likely negative resection margins
  • Nodal stage N0 to N3; resectable nodal disease with extranodal extension allowed at surgeon's discretion
  • Eligible for curative intent treatment with likely negative surgical margins
  • Examination under anesthesia for patients with questionable transoral access prior to randomization
  • Blood work within 4 weeks before randomization showing adequate bone marrow, liver, and kidney function
  • Assessment by both radiation oncologist and surgeon and presentation at multidisciplinary tumor board before randomization
Not Eligible

You will not qualify if you...

  • Serious medical conditions or contraindications to radiotherapy, chemotherapy, or surgery
  • Prior head and neck cancer within the last 5 years
  • Any prior radiation therapy to the head or neck
  • Presence of metastatic disease
  • Inability to complete full radiotherapy course or follow-up visits
  • Prior invasive malignant disease unless disease-free for at least 5 years, excluding non-melanoma skin cancer
  • Unable or unwilling to complete quality of life questionnaires
  • Pregnant or breastfeeding women

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

London Regional Cancer Program

London, Ontario, Canada, N6A 5W9

Actively Recruiting

Loading map...

Research Team

S

Susan Archer

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here